Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
piribedil
- Development stage
- Phase 3
- Lead developer
- Servier Laboratories
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Piribedil is a synthetic non-ergot dopamine agonist primarily used for the treatment of Parkinson's disease and other neurological conditions. It acts as a selective agonist at dopamine D2 and D3 receptors (with higher affinity for D3), and also exhibits antagonistic activity at alpha2-adrenergic receptors. Piribedil improves motor function by stimulating dopamine receptors in the brain and is effective both as monotherapy or in combination with levodopa in early and advanced stages of Parkinson’s disease. Additional indications include management of restless legs syndrome, cognitive impairment (especially age-related memory deficits), peripheral vascular disease (intermittent claudication), dizziness in young patients, retinal ischemic manifestations, anhedonia/apathy in depression (off-label), and enhancement of working memory in older adults. Piribedil has minimal effects on serotonergic, cholinergic, or histaminergic systems[1][3][5][6].
- Brand names
- PronoranTrivastal RetardTrastalTrivastanClarium
- Other names
- piribedilum
02
Targets
ADRA2A (α2A)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)
Beyond the preview
Go deeper on piribedil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on piribedil.